Skip to content
NewsBlazeAU – Lifestyle
Author:
BioVie, Inc.
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 26, 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026
←
Previous Page
1
2